Newsfeeds - Spark Newswire

1 minute read

Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings

Today, 4:55 AM

Citius Pharmaceuticals Inc (NASDAQ:CTXR) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company,…

CTXR

1 minute read

Citius Pharmaceuticals Announces Collaboration With The University Of Pittsburgh To Evaluate T-reg Cell Depletion With I/ONTAK In Combination With Pembrolizumab In Recurrent Or Metastatic Solid Cancer Tumors In A Phase 1 Investigator-Initiated Trial

By Benzinga Newsdesk

Today, 4:55 AM

I/ONTAK plus PD-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients University of Pittsburgh dose-ranging study expected to begin in the fourth quarter of 2022 Collaboration marks second

CTXR

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 4:55 AM

Gainers

ADXN

1 minute read

Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm

By Vandana Singh

Today, 4:55 AM

Citius Pharmaceuticals Inc (NASDAQ:CTXR) plans to form a new company (NewCo) focused on developing and commercializing I/ONTAK. A Phase 3 trial…

CTXR

2 minute read

IPOs
News

Citius Pharmaceuticals, Inc. Announces Intention To Spinoff Late-Stage Oncology Asset, I/ONTAK, Into A New Standalone Publicly Traded Company

By Bill Haddad

Today, 4:55 AM

IPO with distribution of shares to Citius shareholders planned for 2H 2022 Citius would retain Mino-Lok and other pipeline assets and continue to trade on Nasdaq (ticker: CTXR) CRANFORD, N.J., May 25,

CTXR

9 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 4:55 AM

On Friday, 153 companies set new 52-week lows.

ADVM

1 minute read

Citius Pharmaceuticals Q2 EPS $(0.05) Down From $(0.04) YoY

By Benzinga Newsdesk

Today, 4:55 AM

Citius Pharmaceuticals (NASDAQ:CTXR) reported quarterly losses of $(0.05) per share. This is a 25 percent decrease over losses of $(0.04) per share from the same period last year.

CTXR

4 minute read

62 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:55 AM

Gainers Tenon Medical, Inc. (NASDAQ: TNON) rose 350% to clsoe at $22.50 on Wednesday after the company priced its IPO at $5.00 per share.

AFIB

44 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 4:55 AM

Wednesday's session saw 784 companies set new 52-week lows.

AADI

1 minute read

First Patient Dosed in Citius Pharma’s Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

By Ragothaman Srinivasan

Today, 4:55 AM

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids.

CTXR